Liver transplantation with simultaneous splenectomy increases risk of cancer development and mortality in hepatocellular carcinoma patients

doi:10.4240/wjgs.v14.i9.930

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2561)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

138

WORD

HTML

1077

Figures (1-1)

Tables (1-3)

Sum=1446

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

234

Download

881

Sum=1115

Sep 27, 2022 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Sep 27, 2022; 14(9): 930-939
Published online Sep 27, 2022. doi: 10.4240/wjgs.v14.i9.930

Table 1 Patients’ characteristics

	Nonsplenectomy (n = 85)	Splenectomy (n = 35)	P value
Age (yr), median (range)	57 (37-69)	57 (37-69)	0.667
Gender, n (%)			0.107
Male	67 (78.8)	22 (62.9)
Female	18 (21.2)	13 (37.1)
BMI, median (range)	24.2 (17.4-43.8)	24.6 (18.4-43.3)	0.707
Underlying liver disease, n (%)
HBV	66 (77.6)	14 (40.0)	< 0.001^a
HCV	22 (25.9)	23 (65.7)	< 0.001^a
Alcoholism	13 (15.3)	4 (11.4)	0.775
Signs of portal hypertension, n (%)
Ascites	43 (50.6)	19 (54.3)	0.841
Hepatic encephalopathy	35 (41.2)	13 (37.1)	0.838
Varices bleeding	19 (22.4)	12 (34.3)	0.251
Comorbidity, n (%)
Hypertension	20 (23.5)	9 (25.7)	0.817
Diabetes mellitus	40 (47.1)	11 (31.4)	0.155
Preoperative serum tests, median (range)
White blood count (/uL)	4600 (1480-11200)	3500 (1350-12200)	0.120
Platelet count (/uL)	80000 (26000-279000)	64000 (27000-155000)	0.003^a
Neutrophil–lymphocyte ratio	2.44 (0.51-24.18)	3.2 (0.91-21.33)	0.273
Platelet–lymphocyte ratio	78.49 (36.80-284.01)	71.19 (28.53-188.08)	0.386
Total bilirubin (mg/dL)	1.4 (0-38.9)	1.6 (0.4-57.1)	0.984
Creatinine (mg/dL)	0.9 (0.4-10.1)	0.8 (0.5-1.3)	0.578
Ammonia (ug/dL)	99 (0-337)	99 (30-560)	0.737
Albumin (g/dL)	3.2 (1.2-5.3)	3.3 (2.2-5.1)	0.922
Glucose (mg/dL)	115 (0-457)	118 (82-312)	0.956
INR	1.1 (0.9-2.7)	1.2 (0.9-2.1)	0.819
MELD scores	11 (6-32)	11 (6-30)	0.494
AFP (ng/mL)	7.0 (0.5-1190.0)	14.0 (2.0-2170.0)	0.012^a
Surgical factors
Surgical type, n (%)			0.276
DDLT	26 (30.6)	6 (17.1)
LDLT	56 (65.9)	28 (80)
SLT	3 (3.5)	1 (2.9)
Graft type, n (%)			0.120
Whole graft	27 (31.8)	6 (17.1)
Partial graft	58 (68.2)	29 (82.9)
GRWR < 0.8	12 (14.1)	6 (17.1)	0.673
Blood loss (mL), median (range)	1600 (200-14400)	1350 (260-11000)	0.519
Operative time (minutes), median (range)	552 (360-1035)	630 (420-870)	0.001^a
Pathology
Tumor size (cm)	2.2 (0-6.5)	2.5 (0-6.2)	0.140
Tumor number, n (%)			0.404
0 or 1	58 (68.2)	21 (60.0)
2 or 3	27(31.8)	14 (40.0)
Tumor necrosis, n (%)	49 (58.3)	20 (57.1)	1.000
Lymphovascular invasion, n (%)	6 (7.1)	5 (14.3)	0.297
Outcomes
Hospital stays, median (range) (d)	21 (0-85)	18 (5-116)	0.810
HCC Recurrence, n (%)	16 (18.8)	15 (42.9)	0.011^a
Secondary cancer, n (%)	5 (6.4)	0	0.322
Mortality, n (%)	9 (10.6)	11 (31.4)	0.013^a

^aP < 0.05.

BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; GRWR: Graft-to-recipient weight ratio; INR: International normalized ratio; MELD: The Model for End-stage Liver Disease; AFP: α-fetoprotein; LT: Liver transplantation; DDLT: Deceased donor liver transplantation; LDLT: Living donor liver transplantation; SLT: Split liver transplantation.

Table 2 Cox proportional hazard model for cancer-free survival

	Univariate		Multivariate
	Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
Age	1.055 (1.001, 1.112)	0.047^a	1.057 (1.001, 1.117)	0.048^a
Gender/male	1.346 (0.614, 2.950)	0.459	-
BMI	0.937 (0.850, 1.033)	0.191	-
HBV	2.070 (1.005, 4.263)	0.048^a	1.371 (0.632, 2.978)	0.425
HCV	0.687 (0.332-1.423)	0.313	-
Alcoholism	1.751 (0.532-5.769)	0.357	-
Diabetes mellitus	1.062 (0.523, 2.157)	0.868	-
Hypertension	1.704 (0.777, 3.736)	0.183	-
Tumor size	1.057 (0.817, 1.368)	0.672	-
Tumor number (2/3 vs 0/1)	1.577 (0.777, 3.199)	0.207	-
Lymphovascular invasion	1.722 (0.600, 4.945)	0.312	-
Splenectomy	2.754 (1.359, 5.581)	0.005^a	2.560 (1.198, 5.471)	0.015^a
PLT	1.000 (1.000, 1.000)	0.579	-
AFP	1.001 (1.000, 1.002)	0.070	-

^aP < 0.05.

CI: Confidence interval; BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; GRWR: Graft-to-recipient weight ratio; INR: International normalized ratio; MELD: The Model for End-stage Liver Disease; AFP: α-fetoprotein.

Table 3 Cox proportional hazard model for mortality

	Univariate		Multivariate
	Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
Age	1.063 (0.994, 1.136)	0.075	-
Gender/male	1.424 (0.540, 3.757)	0.475	-
BMI	0.942 (0.834, 1.063)	0.333	-
HBV	4.386 (1.719, 11.193)	0.002^a	4.077 (1.001, 16.615)	0.050
HCV	2.853 (1.145, 7.114)	0.024^a	0.661 (0.166, 2.640)	0.558
Alcoholism	0.696 (0.161, 3.018)	0.629	-
Diabetes mellitus	1.640 (0.679, 3.958)	0.271	-
Hypertension	2.872 (1.142, 7.221)	0.025^a	2.813 (1.111, 7.123)	0.029^a
Tumor size	0.944 (0.679, 1.312)	0.732	-
Tumor number (2-3 vs 0-1)	1.911 (0.795, 4.596)	0.148	-
Lymphovascular invasion	2.054 (0.597, 7.062)	0.254	-
Splenectomy	3.656 (1.510, 8.848)	0.004^a	2.791 (1.081, 7.206)	0.034^a
PLT	1.000 (1.000, 1.000)	0.409	-
AFP	1.001 (1.000, 1.002)	0.081	-

^aP < 0.05.

Citation: Fan HL, Hsieh CB, Kuo SM, Chen TW. Liver transplantation with simultaneous splenectomy increases risk of cancer development and mortality in hepatocellular carcinoma patients. World J Gastrointest Surg 2022; 14(9): 930-939
URL: https://www.wjgnet.com/1948-9366/full/v14/i9/930.htm
DOI: https://dx.doi.org/10.4240/wjgs.v14.i9.930